Tag: brusatol

Brusatol increases chemotherapeutic drug efficacy in pancreatic ductal adenocarcinoma by suppressing Nrf2 signaling

Announcing a new publication for Acta Materia Medica journal.  Chemoresistance to gemcitabine (Gem) remains a substantial obstacle in the treatment of pancreatic ductal adenocarcinoma carcinoma (PDAC). Nrf2, a transcription factor responsive to oxidative stress, has been implicated as a key contributor to chemoresistance. Previous studies have demonstrated anti-tumor effects of brusatol (BRT) in PDAC. Herein, […]

Brusatol modulates diverse cancer hallmarks and signaling pathways as a potential cancer therapeutic

Announcing a new review article publication for Acta Materia Medica journal.   Cancer is a consequence of uncontrolled cell proliferation that is associated with cell-cycle disruption. It is a multifactorial disease that depends on the modulation of numerous oncogenic signaling pathways and targets and is a major cause of death worldwide. Because of the development of […]